18F-FDG PET/CT in locally advanced cervical cancer: A review
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Jan-Feb;38(1):59-68.
doi: 10.1016/j.remn.2018.08.004.
Epub 2018 Nov 11.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Medicina Nuclear, UDIAT, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, España. Electronic address: [email protected].
- 2 Departamento de Diagnóstico por Imagen y Medicina Nuclear, Hospital San Pedro-Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, España.
- 3 Servicio de Medicina Nuclear, Hospital Universitario Miguel Servet, Zaragoza, España.
- 4 Servicio de Medicina Nuclear, ERESA, Hospital General Universitario de Valencia, Valencia, España.
- 5 Servicio de Medicina Nuclear, Hospital General Universitario Gregorio Marañón, Madrid, España.
- 6 Unidad de Radiofarmacia, Hospital Universitario Marqués de Valdecilla, Santander, España.
- 7 Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
Abstract
Cervical cancer is the second most common gynecological cancer worldwide. In locally advanced cervical cancer, 18F-FDG PET/CT has become important in the initial staging, particularly in the detection of nodal and distant metastasis, aspects with treatment implications and prognostic value. The aims of this study were to review the role of 18F-FDG PET/CT in uterine cervical cancer, according to the guidelines of the main scientific institutions (FIGO, NCCN, SEGO, SEOM, ESGO, and ESMO) and its diagnostic accuracy compared to conventional radiological techniques, as well as to review the acquisition protocol and its utility in radiotherapy planning, response assessment and detection of recurrence.
Keywords:
(18)F-FDG PET/CT; Cervical cancer; Cáncer de cérvix; Estadificación; PET/TC con (18)F-FDG; Planificación de radioterapia; Radiotherapy planning; Recidiva; Recurrence; Response; Respuesta; Staging.
Copyright © 2018 Sociedad Española de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Female
-
Fluorodeoxyglucose F18*
-
Humans
-
Lymphatic Metastasis
-
Neoplasm Staging
-
Positron Emission Tomography Computed Tomography* / methods
-
Practice Guidelines as Topic
-
Radiopharmaceuticals*
-
Uterine Cervical Neoplasms / diagnostic imaging*
-
Uterine Cervical Neoplasms / pathology
Substances
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18